Why I gave taking antidepressants a second chance with NMOSD
Although taking antidepressants years ago didn't help her mood, columnist Jennifer V. recently decided to give the treatment another try.| Neuromyelitis News
Higher blood levels of the glial fibrillary acidic protein (GFAP) are significantly associated with shrinkage in certain brain regions of people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against the AQP4 protein, a study showed. This association was not observed in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition, further emphasizing […] The post Blood GFAP may be biomarker of brain shrinkage in AQP4-NMOS...| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
A blood test measuring levels of the GPR37 protein may help diagnose neuromyelitis optica spectrum disorder (NMOSD), assess disease severity, and monitor treatment response, according to a new study. The GPR37 test was also able to distinguish NMOSD from multiple sclerosis (MS) and other neurological disorders. “Our findings suggest that GPR37 may serve as a […] The post New GPR37 blood test predicts NMOSD severity, tracks treatment appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
The first time I sat in the infusion chair to receive Ultomiris (ravulizumab-cwvz), I felt something I hadn’t experienced for a long time after being diagnosed with neuromyelitis optica spectrum disorder (NMOSD): hope. I needed this therapy to bring stability back to my life, to spend less time in the emergency department, to stop worrying […] The post After a year of Ultomiris infusions, I finally feel stable appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
More than half of women with neuromyelitis optica spectrum disorder (NMOSD) have never discussed pregnancy with their neurologist, and over 40% report that their pregnancies were unplanned, according to data from a survey-based study in Argentina. This lack of communication means that many women with NMOSD may enter pregnancy without fully understanding the potential risks, […] The post Unplanned pregnancies highlight gaps in care for NMOSD women appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
The moment I slip into a pair of high heels, something shifts. Not only do heels lengthen my legs, but they also boost my confidence, improve my posture, and give me a sense of power. It’s not just about fashion, but also what I associate with high heels: the ability to exude glamor, turn heads, […] The post In my life with NMOSD, wearing high heels is a symbol of resilience appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Although taking antidepressants years ago didn't help her mood, columnist Jennifer V. recently decided to give the treatment another try.| Neuromyelitis News
Get the latest information on neuromyelitis including news, research, treatments, clinical trials, patient stories, and more.| Neuromyelitis News
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Using noninvasive eye scans may help clinicians determine if patients have NMOSD or MS, particularly in early disease stages, a study found.| Neuromyelitis News
A review of nearly 100 articles found that muscle problems are relatively common in NMOSD, affecting more than one-third of patients.| Neuromyelitis News
The gut hormone GLP-1 may drive brain inflammation in NMOSD patients, leading to nausea, vomiting, or hiccups, called area postrema syndrome.| Neuromyelitis News
Bilateral vision loss, the use of a walking aid, fatigue, and depression predict employment loss after a NMOSD diagnosis, a study shows.| Neuromyelitis News
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for...| Neuromyelitis News
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the...| Neuromyelitis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Neuromyelitis News
I always know when it’s been a busy week because my body tells me so. My muscles ache, I feel weak, and a burning sensation finds new areas of my body to light up. I can’t just power through my weekend like others might, enjoying fun activities after the mundane routine of the workweek. Instead, […] The post What it means to be a ‘weekend warrior’ with NMOSD appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor (AHR), is a ligand-activated transcription factor. […] The post AHR protein may be a biomarker for NMOSD relapses appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Enspryng was safe and effective for nearly 9 years in people with NMOSD who have antibodies against AQP4, according to data from two trials.| Neuromyelitis News
Over a recent concert weekend, columnist Jennifer V. and a U.S. friend bonded over the similarities between their cases of NMOSD and MOGAD.| Neuromyelitis News
Nearly all adults with neuromyelitis optica spectrum disorder NMOSD) experience headaches, especially migraines, a study in Iran shows.| Neuromyelitis News
As an immune-compromised NMOSD patient, columnist Jennifer V. wishes others would remember the lessons of the pandemic.| Neuromyelitis News
No description.| Neuromyelitis News
The platelet-to-lymphocyte ratio may be used as a biomarker of disability severity in people with NMOSD, a study found.| Neuromyelitis News
Columnist Jennifer V. explains what "bed rotting" is and how it can be useful for NMOSD patients who need rest and recovery to avoid flares.| Neuromyelitis News
Patricia Inacio is a science writer for Neuromyelitis News with a PhD in cell biology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Margarida Maia is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
Marta Figueiredo is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Living with NMOSD and its resulting disability can make it hard to find and keep employment, a new U.S. study highlights.| Neuromyelitis News
CAR T-cells are able to rapidly eliminate disease-driving immune cells in people with neuromyelitis optica spectrum disorder, or NMOSD.| Neuromyelitis News
NMOSD Awareness Month, featuring events and campaigns, focuses on celebrating milestones while living with the rare neuroimmune disease.| Neuromyelitis News
A family of molecules that can influence immune activity may spot neuromyelitis optica spectrum disorder in people, serving as biomarkers.| Neuromyelitis News
Columnist Jennifer van Amerom reflects on married life with NMO, and expresses her gratitude for her husband, Mike.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
Infections of shingles and cold sores were found to be associated with AQP4 antibody-positive neuromyelitis optica spectrum disorder.| Neuromyelitis News
Uplizna is an FDA-approved treatment for adults with neuromyletis optica spectrum disorder who test positive for AQP4-IgG antibodies.| Neuromyelitis News
Uplizna prevented autoimmune attacks in people with neuromyelitis optica spectrum disorder who received the treatment for four years or more.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
Columnist Candice Galvan shares how she came to realize that to better care for her daughter, she needed to protect her own mental health.| Neuromyelitis News
In her debut column for "The Beginner's Guide to Walking," Jennifer van Amerom describes the role music played in her NMOSD diagnosis.| Neuromyelitis News
A discussion with fellow neuromyelitis optica patients prompts columnist Jennifer van Amerom to address her mental health symptoms.| Neuromyelitis News
Columnist Jennifer Van Amerom knows that reducing stress is a step in the right direction, but she has her own ideas about how to do it.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
NMOSD may begin to manifest as hard-to-treat nausea, vomiting, or hiccups — a condition called area postrema syndrome — delaying a diagnosis.| Neuromyelitis News
Diagnosing NMOSD typically involves a detailed medical history, a thorough clinical evaluation, and specialized imaging and laboratory tests.| Neuromyelitis News
Category archive page for Columns.| Neuromyelitis News
NMOSD patients who have had only one relapse tend to underestimate their future relapse risk, but this pattern changes with more relapses, a study finds.| Neuromyelitis News
Marisa Wexler is a senior science writer for Neuromyelitis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Lindsey Shapiro is a science writer for Neuromyelitis News with a PhD in neuroscience. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Taking ginseng tablets twice a day for three months lessened fatigue in people with NMOSD, a placebo-controlled Phase 3 trial found.| Neuromyelitis News
Rituximab was more efficient at preventing relapses than oral immunosuppressive therapies in a racially diverse group of people with NMOSD.| Neuromyelitis News
Three weeks of low-dose rituximab was found to prevent relapses and disability progression in NMOSD patients, without serious side effects.| Neuromyelitis News
While neuromyelitis optica spectrum disorder's causes are not fully understood, self-reactive antibodies against AQP4 are known major drivers.| Neuromyelitis News
Enspryng (satralizumab-mwge) is an injection therapy approved for adults with neuromyelitis optica spectrum disorder (NMOSD).| Neuromyelitis News
Neuromyelitis optica spectrum disorder affects the optic nerve, spinal cord, and sometimes the brainstem, resulting in a number of symptoms.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Sex ratio and age at onset among NMOSD patients are influenced by the proportion of cases with anti-AQP4 antibodies, a review study found.| Neuromyelitis News
What others may see as mood swings, columnist Jennifer van Amerom argues, are often reactions to trauma or treatment.| Neuromyelitis News
Neuromyelitis optica spectrum disorder patients whose first symptoms affect the brainstem are often misdiagnosed and have more relapses, a study finds.| Neuromyelitis News
With optic neuritis symptoms lingering despite treatment, columnist Jennifer van Amerom is trying to listen to what her body tells her.| Neuromyelitis News
Immunosuppressive therapy is safe and was found to significantly reduce relapses in elderly patients with late-onset NMOSD, per a study.| Neuromyelitis News
After a series of plasma exchange sessions, columnist Jennifer van Amerom is hoping her vision fully returns to normal.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Career changes, new home hunts, and symptom flares are a lot to handle, says columnist Jennifer van Amerom, who's juggling life and NMOSD.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News
